Q2 FY2026 · ended Jun 30, 2026 · Revenue $331,827, -18.9% YoY · Filed Aug 14, 2026
Femasys Inc. (FEMY) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $331,827 and a net loss of $4.5 million. Free cash flow was -$3.9 million. As of Jun 30, 2026 it held $1.4 million in cash and investments and $1.3 million in total debt.
Revenue
$331,827
-18.9% vs year-ago quarter
Net income
$-4.47M
+2.5% vs year-ago quarter
Operating cash flow
$-3.94M
+9.6% vs year-ago quarter
Free cash flow
$-3.95M
+11.3% vs year-ago quarter
EPS
$-1.33
+58.2% vs year-ago quarter
Dividend per share
None
Shares outstanding
8.38M
-74.3% vs year-ago quarter
Net cash
$174,483
Q2 FY2026
Operating margin
-763.9%
TTM
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- FEMY (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Suwanee, GA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1339005
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $331,827 | $424,889 | $813,387 | $729,394 | $409,268 |
| Operating income | -$5.1M | -$4.2M | -$4.6M | -$3.7M | -$3.9M |
| Net income | -$4.5M | $846,100 | -$4.0M | -$4.2M | -$4.6M |
| Diluted EPS | -$1.33 | $0.00 | -$0.06 | -$0.10 | -$3.18 |
| Operating cash flow | -$3.9M | -$4.1M | -$4.2M | -$5.4M | -$4.4M |
| Free cash flow | -$3.9M | -$4.2M | -$4.3M | -$5.6M | -$4.4M |
| Total assets | $12.3M | $16.5M | $20.7M | $16.3M | $13.8M |
| Total liabilities | $8.3M | $9.2M | $14.9M | $11.7M | $12.3M |
| Stockholders' equity | $4.0M | $7.3M | $5.9M | $4.6M | $1.5M |
| Cash and investments | $1.4M | $5.4M | $9.3M | $4.6M | $3.2M |
| Total debt | $1.3M | $1.4M | $1.5M | $1.6M | $1.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Nov 2, 2026 | Oct 30, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 14, 2026 | Aug 14, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Aug 11, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 24, 2026 | Jun 24, 2026 |
| 8-K |
Current report
Other events
|
Jun 24, 2026 | Jun 23, 2026 |
All 341 Femasys Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.